Background: Salbutamol has been shown to mediate anabolic effects after intravenous administration. However, the underlying mechanism responsible for anabolic actions of salbutamol remains unknown.
Objective: To investigate potential mechanism by which salbutamol mediates anabolic effects in vitro.
Methods: Potential androgenic activity of salbutamol was investigated in vitro by the A-Screen assay that measures androgen-dependent inhibition of proliferation of the androgen receptor (AR)-positive human mammary carcinoma cell line, MCF7-AR1.
Results: The assay was validated with three known androgens (methyltrienolone (R1881), 5-αdihydrotestosterone (DHT) and danazol). IC50 values of R1881, DHT and danazol, 4.41 x 10–11, 4.44 x 10-11 and 1.08 x 10-8 M, were in the range known from earlier studies. Our results indicate that salbutamol exhibits androgenic activity, with an IC50 value of 8.93 x 10-6 M. Anti-estrogenic or cytotoxic effects which might have interfered with the assay, were excluded by additional experiments on wildtype MCF7 and MCF7-AR1 cells, respectively.
Conclusion: These data indicate that salbutamol exerts anabolic effects through androgen receptor agonistic activity in vitro.
- androgen receptor
- beta-2 agonist
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.